Updated results from two Phase 1 trials of entrectinib, an investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumours that harbour TRK, ROS1 or ALK fusions—have been published in the journal Cancer Discovery. The studies...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kblVY0
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: April 2017 Source: European Journal of Cancer, Volume 75 Author(s): A. Ieni, G. Angelico, P. Zeppa, G. Tuccari fro...
-
Abstract The quantitative evaluation of Social Science and Humanities (SSH) and the investigation of the existing similarities between SSH...
-
Objective A systematic review and meta-analysis to investigate the impact of electronic nicotine delivery systems (ENDS) and/or electronic n...
-
Sporadic Salmonella outbreaks with varying clinical presentations have been on the rise in various parts of Uganda. The sources of outbreaks...
-
Abstract Purpose Complete mesocolic excision (CME) with central vascular ligation (CVL) has been widely accepted as a surgical treatment...
-
Environmental related durability issues have been of great concerns in the structures strengthened with the fiber reinforced polymers (FRPs)...
-
Abstract Purpose The aim of this study is to assess multi-center reproducibility and longitudinal consistency of MRI imaging measurement...
-
Publication date: Available online 6 November 2017 Source: Academic Radiology Author(s): Clément Orczyk, Andrew B. Rosenkrantz, Artem Mi...
-
Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου